Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 4/20 | 0.44 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642145 | 0.88 | KMT2A (0.48) | SLC6A12KDM5AHMOX1KMT2AMEN1 | |
| SCHEMBL642171 | 0.86 | SLC6A12 (0.50) | CNR1CNR2SLC6A12KDM5AHMOX1 | |
| SCHEMBL642606 | 0.85 | CHRM2 (0.56) | CNR1CNR2KMT2AMEN1L3MBTL1 | |
| SCHEMBL9965413 | 0.85 | CNR1 (0.46) | CNR1CNR2KMT2AMEN1GAA | |
| SCHEMBL642686 | 0.83 | CNR1 (0.51) | CNR1CNR2SLC6A12KDM5AKMT2A | |
| SCHEMBL642227 | 0.82 | CNR1 (0.53) | CNR1CNR2SLC6A12KMT2AMEN1 | |
| SCHEMBL643240 | 0.82 | CNR1 (0.49) | CNR1CNR2SLC6A12KMT2AMEN1 | |
| SCHEMBL642239 | 0.81 | CNR1 (0.49) | CNR1CNR2SLC6A12KMT2AMEN1 | |
| SCHEMBL640952 | 0.81 | ALDH1A1 (0.58) | SLC6A12KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9965382 | 0.80 | PTPN1 (0.51) | KMT2AMEN1GAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | CNR1 23/4885CNR2 33/4885SLC6A12 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.